Bristol-Myers Squibb Co., of New York, said the European Commission approved Opdivo (nivolumab) to treat adult patients with relapsed or refractory classical Hodgkin lymphoma following autologous stem cell transplant and treatment with Adcetris (brentuximab vedotin, Seattle Genetics Inc.).